Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 61 - 69

Published: April 25, 2024

Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated (MASLD), MASLD and increased alcohol intake (MetALD) alcohol‐associated (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) all‐cause mortality among various sub‐groups is unknown. Aims To evaluate MACE death patients with SLD. Methods We conducted nationwide, population‐based study enrolled 761,400 diagnosed MASLD, MetALD or ALD. The primary endpoint was occurrence in Results cumulative incidence were highest ALD, followed by ( p < 0.001 both death), while ALD 0.001). Using as reference adjusting age, sex, smoking, diabetes mellitus, dyslipidaemia hypertension, adjusted hazard ratios (95% confidence intervals) 1.42 (1.1–1.8), 0.68 (0.63–0.73) 1.13 (0.98–1.3), respectively. In they 3.42 (2.6–4.6), 0.58 (0.49–0.67) 1.60 (1.3–2.0), respectively, death. Conclusions can be used to stratify complications prognosis. beneficial stratification identifying mechanisms disease‐specific therapeutic implications.

Language: Английский

---

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(8), P. 1033 - 1041

Published: Aug. 8, 2024

The diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) requires at least one five cardiometabolic criteria. It is unclear whether these criteria can be used as predictors and treatment targets for complications including liver-related events major adverse cardiovascular (MACE).

Language: Английский

---

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Language: Английский

---

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

Language: Английский

---

Deep Learning-Based Prediction Models for Liver-Related and Cardiovascular Events in Steatotic Liver Disease

Published: Jan. 1, 2025

Language: Английский

---

Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma

Cells, Journal Year: 2025, Volume and Issue: 14(6), P. 428 - 428

Published: March 13, 2025

Hepatocellular carcinoma (HCC) is the sixth most common cancer and third leading cause of deaths worldwide. The etiology HCC has now dramatically changed from viral hepatitis to metabolic dysfunction-associated steatotic liver disease (MASLD). main pathogenesis MASLD-related hepatic lipid accumulation hepatocytes, which causes chronic inflammation subsequent progression fibrosis. Chronic generates oxidative stress DNA damage in contribute genomic instability, resulting development HCC. Several molecular pathways are also linked MASLD. In particular, MAPK PI3K-Akt-mTOR upregulated MASLD, promoting survival proliferation cells. addition, MASLD been reported enhance patients with infection. Although there no approved medication for besides resmetirom USA, some preventive strategies onset Sodium-glucose cotransporter-2 (SGLT2) inhibitor, a class medications, exert anti-tumor effects on by regulating reprogramming. Moreover, CD34-positive cell transplantation improves fibrosis intrahepatic angiogenesis supplying various growth factors. Furthermore, exercise through an increase energy consumption as well changes chemokines myokines. this review, we summarize recent progress made pathogenic mechanisms MASLD-associated introduced new therapeutic preventing based

Language: Английский

---

AI‐Based Platelet‐Independent Noninvasive Test for Liver Fibrosis in MASLD Patients

JGH Open, Journal Year: 2025, Volume and Issue: 9(4)

Published: April 1, 2025

Noninvasive tests (NITs), such as platelet-based indices and ultrasound/MRI elastography, are widely used to assess liver fibrosis in metabolic dysfunction-associated steatotic disease (MASLD). However, platelet counts not routinely included Japanese health check-ups, limiting their utility large-scale screenings. Additionally, while effective, is costly less accessible routine practice. Most existing AI-based models incorporate these markers, restricting applicability. This study aimed develop a simple yet accurate AI model for staging using only demographic biochemical markers. retrospective analyzed biopsy-proven data from 463 MASLD patients. Patients were randomly assigned training (N = 370, 80%) test 93, 20%) cohorts. The incorporated age, sex, BMI, diabetes, hypertension, hyperlipidemia, blood markers (AST, ALT, γ-GTP, HbA1c, glucose, triglycerides, cholesterol). Support Vector Machine demonstrated high diagnostic performance, with an area under the curve (AUC) of 0.886 detecting significant (≥ F2). AUCs advanced F3) cirrhosis (F4) 0.882 0.916, respectively. Compared FIB-4, APRI, FAST score (0.80-0.96), SVM achieved comparable accuracy eliminating need count or elastography. accurately assesses patients without requiring Its simplicity, cost-effectiveness, strong performance make it well-suited screenings clinical use.

Language: Английский

---

Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD

Diabetes Research and Clinical Practice, Journal Year: 2024, Volume and Issue: 217, P. 111820 - 111820

Published: Aug. 13, 2024

Language: Английский

---

Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 30, 2024

Abstract Aim The aim was to examine the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD), a risk factor for atherosclerotic cardiovascular disease, and its association with glycaemic control metrics in children adolescents type 1 diabetes (T1D). Materials Methods We enrolled 244 T1D (115 girls, mean age: 16.2 ± 3.2 years). diagnosis MASLD defined by presence hepatic steatosis on ultrasonography combination at least one five common cardiometabolic factors. Metrics short‐term long‐term control, blood pressure, lipids, anthropometric characteristics three genetic variants strongly related susceptibility (rs738409 [patatin‐like phospholipase domain‐containing 3], rs58542926 [transmembrane 6 superfamily member 2] rs1260326 [glucokinase regulator]) were assessed. Characteristics these subjects without compared using unpaired Student t test, Mann–Whitney test or χ 2 as appropriate. Logistic regression analyses performed determine main independent predictors MASLD. Results 27.5% T1D. Blood total cholesterol, low‐density lipoprotein (LDL) non‐high‐density HbA1c time above range (TAR) significantly higher than those Mean values from onset (adjusted odds ratio [OR]: 1.703, 95% confidence interval [CI]: 1.040–2.787, p = 0.034), TAR OR: 1.028, CI: 1.009–1.047, 0.006) plasma LDL cholesterol 1.045, 1.013–1.078, 0.004) independently associated Conclusions is condition onset, levels

Language: Английский

---

Editorial: Multi-organ linkage pathophysiology and therapy for NAFLD and NASH

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: June 5, 2024

Keywords: non alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatotic (MASLD), (MASH), multi-organ linkage

Language: Английский

---